Cancer Research and Treatment

Original Articles

CNS cancer

Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study): Grace S. Ahn, Kihwan Hwang, Tae Min Kim, Chul Kee Park, Jong Hee Chang, Tae-Young Jung, Jin Hee Kim, Do-Hyun Nam, Se-Hyuk Kim, Heon Yoo, Yong-Kil Hong, Eun-Young Kim, Dong-Eun Lee, Jungnam Joo, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Seok-Gu Kang, Jeong Hoon Kim, Chae-Yong Kim; Cancer Res Treat. 2022;54(2):396-405. Published online July 6, 2021; DOI: https://doi.org/10.4143/crt.2021.393

Abstract PDF Supplementary Material PubReader ePub

Purpose
The KNOG-1101 study showed improved 2-year PFS with temozolomide during and after radiotherapy compared to radiotherapy alone for patients with anaplastic gliomas. This trial investigates the effect of concurrent and adjuvant temozolomide on health-related quality of life (HRQoL).
Materials and Methods
In this randomized, open-label, phase II trial, 90 patients with World Health Organization grade III glioma were enrolled across multiple centers in South Korea between March 2012 to February 2015 and followed up through 2017. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-C30) and 20-item EORTC QLQ-Brain Neoplasm (QLQ-BN20) were used to compare HRQoL between patients assigned to concurrent chemoradiotherapy with temozolomide followed by 6 cycles of adjuvant temozolomide (arm A) and radiotherapy (RT) alone (arm B).
Results
Of the 90 patients in the study, 84 patients (93.3%) completed the baseline HRQoL questionnaire. Emotional functioning, fatigue, nausea and vomiting, dyspnea, constipation, appetite loss, diarrhea, seizures, itchy skin, drowsiness, hair loss, and bladder control were not affected by the addition of temozolomide. All other items did not differ significantly between arm A and arm B throughout treatment. Global health status particularly stayed consistent at the end of adjuvant temozolomide (p=0.47) and at the end of RT (p=0.33).
Conclusion
The addition of concurrent and adjuvant temozolomide did not show negative influence on HRQoL with improvement of progression-free survival for patients with anaplastic gliomas. The absence of systematic and clinically relevant changes in HRQoL suggests that an overall long-term net clinical benefit exists for concurrent and adjuvant temozolomide.

Citations

Citations to this article as recorded by

Achievements of international rare cancers networks and consortia in the neuro-oncology field
Vincenzo Di Nunno, Enrico Franceschi, Ahmed Idbaih
Current Opinion in Oncology.2024; 36(6): 554. CrossRef
Prevalence and management of sleep disturbance in adults with primary brain tumours and their caregivers: a systematic review
Jason A. Martin, Nicolas H. Hart, Natalie Bradford, Fiona Naumann, Mark B. Pinkham, Elizabeth P. Pinkham, Justin J. Holland
Journal of Neuro-Oncology.2023; 162(1): 25. CrossRef
Prolonged use of temozolomide leads to increased anxiety and decreased content of aggrecan and chondroitin sulfate in brain tissues of aged rats
Anastasia Strokotova, Dmitry Sokolov, Olga Molodykh, Elena Koldysheva, Evgenii Kliver, Victor Ushakov, Maxim Politko, Nadezhda Mikhnevich, Galina Kazanskaya, Svetlana Aidagulova, Elvira Grigorieva
Biomedical Reports.2023;[Epub] CrossRef

8,152 View
164 Download
4 Web of Science
3 Crossref

Lung cancer

Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase–Low Squamous Cell Lung Cancer: Mihong Choi, Heung Tae Kim, Ji-Youn Han, Geon Kook Lee, Soo-Hyun Lee, Kun Young Lim, Jungnam Joo, Hye Jin Won, Jin Soo Lee, Youngjoo Lee; Cancer Res Treat. 2021;53(1):87-92. Published online August 13, 2020; DOI: https://doi.org/10.4143/crt.2020.741

Abstract PDF Supplementary Material PubReader ePub

Purpose
Squamous cell carcinomas (SqCC) of the lung often express high levels of thymidylate synthase (TS), which is associated with primary resistance to pemetrexed. We explored the efficacy of pemetrexed in a selected population of patients with lung SqCC with low TS expression.
Materials and Methods
In this single-arm phase II trial, we enrolled 32 previously-treated patients with advanced lung SqCC exhibiting low immunohistochemical staining for TS (i.e., in 10% or less of tumor cells). The primary endpoint was 12-week progression-free survival (PFS) rate.
Results
Of 32 patients, eight patients (25%) had an Eastern Cooperative Oncology Group performance status of 2, and seven patients (22%) had previously received three or more lines of chemotherapy. The disease control rate from pemetrexed treatment was 30%, and no objective response was observed. The 12-week PFS rate was 24.5% (95% confidence interval [CI], 13.0 to 46.1). Median PFS was 1.3 months (95% CI, 1.3 to 2.7), and median overall survival was 11.8 months (95% CI, 8.1 to not applicable). Most of adverse events were grade 1 or 2.
Conclusion
Pemetrexed demonstrated modest activity as a salvage chemotherapy in patients with advanced lung SqCC with low TS expression, although its toxicity was generally manageable.

Citations

Citations to this article as recorded by

Bioengineered miR-7-5p modulates non–small cell lung cancer cell metabolism to improve therapy
Gavin M. Traber, Mei-Juan Tu, Su Guan, Neelu Batra, Ai-Ming Yu
Molecular Pharmacology.2025; 107(1): 100006. CrossRef

7,136 View
129 Download
1 Crossref

Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study): Kihwan Hwang, Tae Min Kim, Chul-Kee Park, Jong Hee Chang, Tae-Young Jung, Jin Hee Kim, Do-Hyun Nam, Se-Hyuk Kim, Heon Yoo, Yong-Kil Hong, Eun-Young Kim, Dong-Eun Lee, Jungnam Joo, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Seok-Gu Kang, Jeong Hoon Kim, Chae-Yong Kim; Cancer Res Treat. 2020;52(2):505-515. Published online October 28, 2019; DOI: https://doi.org/10.4143/crt.2019.421

Abstract PDF PubReader ePub

Purpose
We investigated the efficacy of temozolomide during and after radiotherapy in Korean adults with anaplastic gliomas without 1p/19q co-deletion.
Materials and Methods
This was a randomized, open-label, phase 2 study and notably the first multicenter trial for Korean grade III glioma patients. Eligible patients were aged 18 years or older and had newly diagnosed non-co-deleted anaplastic glioma with an Eastern Cooperative Oncology Group performance status of 0-2. Patients were randomized 1:1 to receive radiotherapy alone (60 Gy in 30 fractions of 2 Gy) (control group, n=44) or to receive radiotherapy with concurrent temozolomide (75 mg/m²/day) followed by adjuvant temozolomide (150-200 mg/m²/day for 5 days during six 28-day cycles) (treatment group, n=40). The primary end-point was 2-year progression-free survival (PFS). Seventy patients (83.3%) were available for the analysis of the isocitrate dehydrogenase 1 gene (IDH1) mutation status.
Results
The two-year PFS was 42.2% in the treatment group and 37.2% in the control group. Overall survival (OS) did not reach to significant difference between the groups. In multivariable analysis, age was a significant risk factor for PFS (hazard ratio [HR], 2.08; 95% confidence interval [CI], 1.04 to 4.16). The IDH1 mutation was the only significant prognostic factor for PFS (HR, 0.28; 95% CI, 0.13 to 0.59) and OS (HR, 0.19; 95% CI, 0.07 to 0.50). Adverse events over grade 3 were seen in 16 patients (40.0%) in the treatment group and were reversible.
Conclusion
Concurrent and adjuvant temozolomide in Korean adults with newly diagnosed non-co- deleted anaplastic gliomas showed improved 2-year PFS. The survival benefit of this regimen needs further analysis with long-term follow-up at least more than 10 years.

Citations

Citations to this article as recorded by

Impact of upfront adjuvant chemoradiation on survival in patients with molecularly defined oligodendroglioma: the benefits of PCV over TMZ
Jordina Rincon-Torroella, Maureen Rakovec, Anita L. Kalluri, Kelly Jiang, Carly Weber-Levine, Megan Parker, Divyaansh Raj, Josh Materi, Sadra Sepehri, Abel Ferres, Karisa C. Schreck, Iban Aldecoa, Calixto-Hope G. Lucas, Haris I. Sair, Kristin J. Redmond,
Journal of Neuro-Oncology.2025; 171(1): 35. CrossRef
Multidisciplinary Management of Isocitrate Dehydrogenase–Mutated Gliomas in a Contemporary Molecularly Defined Era
Rupesh Kotecha, David Schiff, Arnab Chakravarti, Jessica L. Fleming, Paul D. Brown, Vinay K. Puduvalli, Michael A. Vogelbaum, Vinai Gondi, Marco Gallus, Hideho Okada, Minesh P. Mehta
Journal of Clinical Oncology.2024; 42(21): 2588. CrossRef
The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas
Connor J Kinslow, Soumyajit Roy, Fabio M Iwamoto, Paul D Brown, David M DeStephano, Peter D Canoll, Summer S Qureshi, Matthew Gallito, Michael B Sisti, Jeffrey N Bruce, David P Horowitz, Lisa A Kachnic, Alfred I Neugut, James B Yu, Minesh P Mehta, Simon K
Neuro-Oncology.2024; 26(10): 1839. CrossRef
The Role of Systemic Therapies in the Treatment of Grades 1-4 Gliomas
Jan Stepka, Mariusz Dotka, Maciej Kosiński, Piotr Suchecki, Maciej Hobot, Igor Piotrowski
Cureus.2024;[Epub] CrossRef
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline
Nimish A. Mohile, Hans Messersmith, Na Tosha Gatson, Andreas F. Hottinger, Andrew Lassman, Jordan Morton, Douglas Ney, Phioanh Leia Nghiemphu, Adriana Olar, Jeffery Olson, James Perry, Jana Portnow, David Schiff, Anne Shannon, Helen A. Shih, Roy Strowd, M
Journal of Clinical Oncology.2022; 40(4): 403. CrossRef
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline
Nimish A Mohile, Hans Messersmith, Na Tosha N Gatson, Andreas F Hottinger, Andrew B Lassman, Jordan Morton, Douglas Ney, Phioanh Leia Nghiemphu, Adriana Olar, Jeffery Olson, James Perry, Jana Portnow, David Schiff, Anne Shannon, Helen A Shih, Roy Strowd,
Neuro-Oncology.2022; 24(3): 358. CrossRef
Executive summary of American Radium Society’s appropriate use criteria for the postoperative management of lower grade gliomas
Martin C. Tom, Michael T. Milano, Samuel T. Chao, Scott G. Soltys, Jonathan P.S. Knisely, Arjun Sahgal, Seema Nagpal, Simon S. Lo, Siavash Jabbari, Tony J.C. Wang, Manmeet S. Ahluwalia, Marian Simonson, Joshua D. Palmer, Melanie Hayden Gephart, Lia M. Hal
Radiotherapy and Oncology.2022; 170: 79. CrossRef
Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study)
Grace S. Ahn, Kihwan Hwang, Tae Min Kim, Chul Kee Park, Jong Hee Chang, Tae-Young Jung, Jin Hee Kim, Do-Hyun Nam, Se-Hyuk Kim, Heon Yoo, Yong-Kil Hong, Eun-Young Kim, Dong-Eun Lee, Jungnam Joo, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Seok-Gu Kang, Jeo
Cancer Research and Treatment.2022; 54(2): 396. CrossRef
The Risk of Heart Disease-Related Death Among Anaplastic Astrocytoma Patients After Chemotherapy: A SEER Population-Based Analysis
Qi Lin, Jia-Hao Bao, Fei Xue, Jia-Jun Qin, Zhen Chen, Zhong-Rong Chen, Chao Li, Yi-Xuan Yan, Jin Fu, Zhao-Li Shen, Xian-Zhen Chen
Frontiers in Oncology.2022;[Epub] CrossRef
Association between a prior cancer history and prognosis in adult patients with high‑grade glioma
Dongjie He, Peiwen Wu, Gaiyan Li, Siying Zhu, Qiming Wang, Qiuju Shao, Hao Chang
Journal of Clinical Neuroscience.2022; 106: 20. CrossRef

9,716 View
635 Download
9 Web of Science
10 Crossref

Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry: Jung Kwon Kim, Sung Han Kim, Mi Kyung Song, Jungnam Joo, Seong Il Seo, Cheol Kwak, Chang Wook Jeong, Cheryn Song, Eu Chang Hwang, Ill Young Seo, Hakmin Lee, Sung-Hoo Hong, Jae Young Park, Jinsoo Chung, Korean Renal Cell Carcinoma Study Group; Cancer Res Treat. 2019;51(2):758-768. Published online September 7, 2018; DOI: https://doi.org/10.4143/crt.2018.421

Abstract PDF Supplementary Material PubReader ePub

Purpose
The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Memorial Sloan Kettering Cancer Center (MSKCC) risk models were developed predominantly with clear cell renal cell carcinoma (RCC). Accordingly, whether these two models could be applied to metastatic non-clear cell RCC (mNCCRCC) as well has not been well-known and was investigated herein.
Materials and Methods
From the Korean metastatic RCC registry, a total of 156 patients (8.1%) with mNCCRCC among the entire cohort of 1,922 patients were analyzed. Both models were applied to predict first-line progression-free survival (PFS), total PFS, and cancer-specific survival (CSS).
Results
The median first-line PFS, total PFS, and CSS were 5, 6, and 24 months, respectively. The IMDC risk model reliably discriminated three risk groups to predict survival: the median firstline PFS, total PFS, and CSS for the favorable, intermediate, and poor risk groups were 9, 5, and, 2 months (p=0.001); 14, 7, and 2 months (p < 0.001); and 41, 21, and 8 months (p < 0.001), all respectively. The MSKCC risk model also reliably differentiated three risk groups: 9, 5, and, 2 months (p=0.005); 10, 7, and 3 months (p=0.002); and 50, 21, and 8 months (p < 0.001), also all respectively. The concordance indices were 0.632 with the IMDC model and 0.643 with the MSKCC model for first-line PFS: 0.748 and 0.655 for CSS.
Conclusion
The current IMDC and MSKCC risk models reliably predict first-line PFS, total PFS, and CSS in mNCCRCC.

Citations

Citations to this article as recorded by

Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options
Nathaniel R. Wilson, Yusuf Acikgoz, Elshad Hasanov
International Journal of Cancer.2024; 154(6): 947. CrossRef
Survival pattern of metastatic renal cell carcinoma patients according to WHO/ISUP grade: a long-term multi-institutional study
Joongwon Choi, Seokhwan Bang, Jungyo Suh, Chang Il Choi, Wan Song, Hyeong Dong Yuk, Chan Ho Lee, Minyong Kang, Seol Ho Choo, Jung Kwon Kim, Hyung Ho Lee, Jung Ki Jo, Eu Chang Hwang, Chang Wook Jeong, Young Hwii Ko, Jae Young Park, Cheryn Song, Seong Il Se
Scientific Reports.2024;[Epub] CrossRef
Prognostic Factors and Treatment Outcomes in Renal Cell Carcinoma: A Comprehensive Analysis
Ömer Faruk ELÇİÇEK, Mehmet KÜÇÜKÖNER
Namık Kemal Tıp Dergisi.2024; : 217. CrossRef
High Sensitivity Circulating Tumor-DNA Assays in Renal Cell Carcinoma–Are we there yet?
Fady Sidhom, Shefali Patel, Arpita Desai, Arnab Basu
Clinical Genitourinary Cancer.2024; 22(6): 102235. CrossRef
Machine learning based prediction for oncologic outcomes of renal cell carcinoma after surgery using Korean Renal Cell Carcinoma (KORCC) database
Jung Kwon Kim, Sangchul Lee, Sung Kyu Hong, Cheol Kwak, Chang Wook Jeong, Seok Ho Kang, Sung-Hoo Hong, Yong-June Kim, Jinsoo Chung, Eu Chang Hwang, Tae Gyun Kwon, Seok-Soo Byun, Yu Jin Jung, Junghyun Lim, Jiyeon Kim, Hyeju Oh
Scientific Reports.2023;[Epub] CrossRef
Targeted Literature Review of Outcomes to Initial Systemic Therapy for Advanced/Metastatic Non-Clear Cell Renal Cell Carcinoma in Observational Studies
Shawna R. Calhoun, Manish Sharma, Chung-Han Lee
Kidney Cancer.2023; 7(1): 123. CrossRef
A retrospective single-centered, comprehensive targeted genetic sequencing analysis of prognostic survival using tissues from Korean patients with metastatic renal cell carcinoma after targeted therapy
Sung Han Kim, Jongkeun Park, Weon Seo Park, Dongwan Hong, Jinsoo Chung
Investigative and Clinical Urology.2022; 63(6): 602. CrossRef
Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry
Ilya Tsimafeyeu, Oxana Shatkovskaya, Sergei Krasny, Nurzhan Nurgaliev, Ilya Varlamov, Vladislav Petkau, Sufia Safina, Ruslan Zukov, Mikhail Mazhbich, Galina Statsenko, Sergey Varlamov, Olga Novikova, Igor Zaitsev, Pavel Moiseyev, Alexander Rolevich, Alesy
Cancer Reports.2021;[Epub] CrossRef
The prognostic effect of immunoscore in patients with clear cell renal cell carcinoma: preliminary results
Ismail Selvi, Umut Demirci, Nazan Bozdogan, Halil Basar
International Urology and Nephrology.2020; 52(1): 21. CrossRef
Life expectancy in patients with metastatic renal cell carcinoma in the Russian Federation: results of the RENSUR3 multicenter registry study
I. V. Tsimafeyeu, I. S. Varlamov, V. V. Petkau, S. Z. Safina, R. A. Zukov, M. S. Mazhbich, G. B. Statsenko, S. A. Varlamov, I. V. Zaitsev, O. Yu. Novikova, S. А. Krasny, N. S. Nurgaliyev, I. L. Popova, L. Yu. Vladimirova
Malignant tumours.2019; 9(2): 45. CrossRef

10,709 View
244 Download
12 Web of Science
10 Crossref

Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers: Eun-Gyeong Lee, Hyok Jo Kang, Myong Cheol Lim, Boyoung Park, Soo Jin Park, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Sang-Yoon Park, Boram Park, Jungnam Joo, Jai Hong Han, Sun-Young Kong, Eun Sook Lee; Cancer Res Treat. 2019;51(1):280-288. Published online May 4, 2018; DOI: https://doi.org/10.4143/crt.2018.079

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to investigate decision patterns to reduce the risks of BRCArelated breast and gynecologic cancers in carriers of BRCA pathogenic variants. We found a change in risk-reducing (RR) management patterns after December 2012, when the National Health Insurance System (NHIS) of Korea began to pay for BRCA testing and riskreducing salpingo-oophorectomy (RRSO) in pathogenic-variant carriers.
Materials and Methods
The study group consisted of 992 patients, including 705 with breast cancer (BC), 23 with ovarian cancer (OC), 10 with both, and 254 relatives of high-risk patients who underwent BRCA testing at the National Cancer Center of Korea from January 2008 to December 2016.We analyzed patterns of and factors in RR management.
Results
Of the 992 patients, 220 (22.2%) were carriers of BRCA pathogenic variants. About 92.3% (203/220) had a family history of BC and/or OC,which significantly differed between BRCA1 and BRCA2 carriers (p < 0.001). All 41 male carriers chose surveillance. Of the 179 female carriers, 59 of the 83 carriers (71.1%) with BC and the 39 of 79 unaffected carriers (49.4%) underwent RR management. None of the carriers affected with OC underwent RR management. Of the management types, RRSO had the highest rate (42.5%) of patient choice. The rate of RR surgery was significantly higher after 2013 than before 2013 (46.3% [74/160] vs. 31.6% [6/19], p < 0.001).
Conclusion
RRSO was the preferred management for carriers of BRCA pathogenic variants. The most important factors in treatment choice were NHIS reimbursement and/or the severity of illness.

Citations

Citations to this article as recorded by

A Scoping Review of Primary Breast Cancer Risk Reduction Strategies in East and Southeast Asia
Filipa Alpeza, Christine Kim Yan Loo, Qingyuan Zhuang, Mikael Hartman, Serene Si Ning Goh, Jingmei Li
Cancers.2025; 17(2): 168. CrossRef
Risk-reducing decisions regarding germlineBRCApathogenic variant: focusing on the timing of genetic testing and RRSO
Akiko Abe, Hidetaka Nomura, Atsushi Fusegi, Mayu Yunokawa, Arisa Ueki, Eri Habano, Hiromi Arakawa, Keika Kaneko, Yuko Minoura, Hitoshi Inari, Takayuki Ueno, Hiroyuki Kanao
Journal of Medical Genetics.2024; 61(4): 392. CrossRef
BRCA Mutation Patients: Are There Other Predisposing Factors for Ovarian Cancer Occurrence? A Multicenter Retrospective Study
Vera Loizzi, Michele Mongelli, Francesca Arezzo, Isabella Romagno, Gerardo Cazzato, Ondina Popescu, Francesco Legge, Paolo Trerotoli, Erica Silvestris, Anila Kardhashi, Gennaro Cormio
Gynecologic and Obstetric Investigation.2024; 89(2): 87. CrossRef
Implementation of BRCA Test among Young Breast Cancer Patients in South Korea: A Nationwide Cohort Study
Yung-Huyn Hwang, Tae-Kyung Yoo, Sae Byul Lee, Jisun Kim, Beom Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Il Yong Chung
Cancer Research and Treatment.2024; 56(3): 802. CrossRef
Pattern Anlysis of Risk-Reducing Strategies in Unaffected Korean BRCA1/2 Mutation Carriers
Dabin Kim, Jai Min Ryu, Sang-Ah Han, Zisun Kim, Sung-Won Kim
Current Oncology.2024; 31(11): 6767. CrossRef
Impact of graphical display on the intention to undergo risk-reducing salpingo-oophorectomy and mastectomy in individuals positive for BRCA pathogenic variant
Yoon-Jung Choi, Younju Park, Boyoung Park, Heejung Chae, So-Youn Jung, Kum Hei Ryu, Myong Cheol Lim, Soo Jin Park, Yoon Jung Chang, Sun-Young Kong
Scientific Reports.2024;[Epub] CrossRef
Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan
Hidetaka Nomura, Akiko Abe, Atsushi Fusegi, Teruyuki Yoshimitsu, Satoki Misaka, Atsushi Murakami, Tsuyoshi Matsumoto, Shiho Tsumura, Motoko Kanno, Yoichi Aoki, Sachiho Netsu, Makiko Omi, Terumi Tanigawa, Sanshiro Okamoto, Kohei Omatsu, Mayu Yunokawa, Hiro
Scientific Reports.2023;[Epub] CrossRef
Characteristics of second primary breast cancer after ovarian cancer: a Korea central cancer registry retrospective study
Eun-Gyeong Lee, Jiwon Lim, Hyeong In Ha, Myong Cheol Lim, Yoon Jung Chang, Young-Joo Won, So-Youn Jung
Frontiers in Oncology.2023;[Epub] CrossRef
Differences in Willingness to Undergo BRCA1/2 Testing and Risk Reducing Surgery among the General Public, Cancer Patients, and Healthcare Professionals: A Large Population-Based Survey
Yoon Jung Chang, Seungyeon Cho, Jungnam Joo, Kum Hei Ryu, Sangwon Lee, Juhee Cho, Myong Cheol Lim, So-Youn Jung, Jai Hong Han, Eun Sook Lee, Sun-Young Kong
Journal of Personalized Medicine.2022; 12(5): 818. CrossRef
Management of patients with BRCA mutation from the point of view of a breast surgeon
M.L. Riis
Annals of Medicine and Surgery.2021; 65: 102311. CrossRef
Disparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Young Min Hur, Jaehee Mun, Mi-Kyung Kim, Maria Lee, Yun Hwan Kim, Seung-Cheol Kim
Journal of Korean Medical Science.2021;[Epub] CrossRef
Clinical significance of gene polymorphisms for hereditary predisposition to breast and ovarian cancer (review of literature)
D. I. Vodolazhsky, A. V. Mayakovskaya, A. V. Kubyshkin, K. A. Aliev, I. I. Fomochkina
Russian Clinical Laboratory Diagnostics.2021; 66(12): 760. CrossRef
Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of the BRCA1/2 Mutation
Sung Mi Jung, Jai Min Ryu, Hyung Seok Park, Ji Soo Park, Eunyoung Kang, Seeyoun Lee, Han-Byoel Lee, Hyun Jo Youn, Tae-Kyung Yoo, Jisun Kim, Jeong Eon Lee, Sang Ah Han, Dongwon Kim, Sung-Won Kim
Journal of Breast Cancer.2020; 23(6): 647. CrossRef

10,942 View
230 Download
15 Web of Science
13 Crossref

Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: Maria Lee, Yumi Lee, Kidong Kim, Eun Young Park, Myong Cheol Lim, Jung-Sup Kim, Hee Seung Kim, Yong-Beom Kim, Yong-Man Kim, Jungnam Joo, Sang Yoon Park, Chel Hun Choi, Jae-Hoon Kim; Cancer Res Treat. 2019;51(1):112-118. Published online March 7, 2018; DOI: https://doi.org/10.4143/crt.2017.361

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to develop Korean versions of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy (NCCN-FACT) Ovarian Symptom Index-18 (NFOSI-18) and FACT/Gynecologic Oncology Group (FACT-GOG) Neurotoxicity 4-item (NTX-4), evaluating their reliability and reproducibility.
Materials and Methods
In converting NFOSI-18 and NTX-4, the following steps were performed: forward translation, backward translation, expert review, pretest of preliminary format, and finalization of Korean versions (K-NFOSI-18 and K-NTX-4). Patients were enrolled from six institutions where each had completed chemotherapy for ovarian, tubal, or peritoneal cancer at least 1 month earlier. In addition to demographics obtained by questionnaire, all subjects were assessed via K-NFOSI-18, K-NTX-4, and a Korean version of the EuroQoL-5 Dimension. Internal structural validity and reliability were evaluated using item internal consistency, item discriminant validity, and Cronbach's α. To evaluate test-retest reliability, K-NFOSI-18 and K-NTX-4 were readministered after 7-21 days, and intraclass correlation coefficients (ICCs) were calculated.
Results
Of the 250 women enrolled during the 3-month recruitment period, 13 withdrew or did not respond, leaving 237 (94.8%) for the analyses. Mean patient age was 54.3±10.8 years. Re-testing was performed in 190 patients (80.2%). The total K-NFOSI-18 and K-NTX-4 scores were 49 (range, 20 to 72) and 9 (range, 0 to 16), respectively, with high reliability (Cronbach's α=0.84 and 0.89, respectively) and reproducibility (ICC=0.77 and 0.84, respectively) achieved in retesting.
Conclusion
Both NFOSI-18 and NTX-4 were successfully developed in Korean with minimal modification. Each Korean version showed high internal consistency and reproducibility.

Citations

Citations to this article as recorded by

Peripheral Neuropathy Instruments for Individuals with Cancer: A COSMIN-Based Systematic Review of Measurement Properties
Silvia Belloni, Arianna Magon, Chiara Giacon, Francesca Savioni, Gianluca Conte, Rosario Caruso, Cristina Arrigoni
Current Oncology.2024; 31(12): 7828. CrossRef
Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review
Charlotte L Moss, Teresa Guerrero-Urbano, Ingrid White, Benjamin Taylor, Rebecca Kristeleit, Ana Montes, Louis Fox, Katharina Beyer, Monika Sztankay, Maria M Ratti, Elena S Sisca, Alexandra Derevianko, Steven MacLennan, Nicholas Wood, Lisa M Wintner, Miek
Future Oncology.2023; 19(9): 663. CrossRef
Validity and Reliability of the Turkish Version of National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18) and Neurotoxicity-4 (NTX-4) for Patients with Advanced Ovarian Cancer
Husnu Tore Yavuzsen, Sukriye Cansu Gulteki̇n, Karya Polat, Murat Keser, Zeynep Gulsum Guc, Merve Keskinkilic, Tugba Yavuzsen, Didem Karadibak, Sourav Panja
European Journal of Cancer Care.2023; 2023: 1. CrossRef
Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use
Tiffany Li, Susanna B. Park, Eva Battaglini, Madeleine T. King, Matthew C. Kiernan, David Goldstein, Claudia Rutherford
Quality of Life Research.2022; 31(11): 3091. CrossRef
Influence of chemotherapy on postural control and quality of life in women with gynaecological cancer: a protocol of a prospective observational study
Aline Reinmann, Anne-Violette Bruyneel, Joseph Gligorov, Serge Mesure, Christophe Combescure, Thibaud Koessler, Alexandre Bodmer
BMJ Open.2022; 12(9): e061664. CrossRef

8,183 View
185 Download
5 Web of Science
5 Crossref

Development and Evaluation of a Korean Version of a Thyroid-Specific Quality-of-Life Questionnaire Scale in Thyroid Cancer Patients: Chang Hwan Ryu, Boram Park, Junsun Ryu, Youn Mi Ryu, Seong Ae Jo, You Jin Lee, Eun-Kyung Lee, Yul Hwangbo, Jungnam Joo, Yuh-Seog Jung; Cancer Res Treat. 2018;50(2):405-415. Published online May 26, 2017; DOI: https://doi.org/10.4143/crt.2017.012

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to develop a Korean version of the self-reported thyroid-specific quality of life (QoL) questionnaire for thyroid cancer patients (KT-QoL), and to evaluate its reliability and validity.
Materials and Methods
Two hundred seventy-two patients who underwent thyroidectomy from January to December 2010 were recruited in this study. The original version of the thyroid QoL was translated into Korean and evaluated for its reliability and validity. Using the developed KT-QoL, the postoperative QoL was evaluated until postoperative 1 year.
Results
At the preoperative baseline, the item internal consistency (IIC) ranged from ‒0.19 to 0.76, with low IIC values for items 2, 17, and 27. Item discriminant validity ranged from 86% to 97%. These values were similar at the postoperative periods. The internal consistency reliability (Cronbach’s α) was high for all dimensions, ranging from 0.90 to 0.95. The test-retest reliability (intraclass correlation coefficient) was acceptable (0.74-0.82). The external validity examined by the correlation between the item 1j (voice changes) of KT-QoL and the voice handicap index-30 ranged from 0.51 to 0.75. Patients’ QoL scores decreased after surgery, which demonstrated the sensitivity of the questionnaire. The QoL scores in patients with lobectomy showed best QoL scores postoperatively and those with receiving radioactive iodine still showed decreased QoL scores along the postoperative periods.
Conclusion
These results demonstrate that KT-QoL is a valid instrument for evaluating QoL of Korean patients with thyroid cancer.

Citations

Citations to this article as recorded by

Laryngeal Electromyography as a Predictive Factor in the Evolution of Unilateral Recurrent Paralysis Post-Thyroidectomy
Shirley Tarabichi, Codrut Sarafoleanu
Journal of Clinical Medicine.2025; 14(4): 1047. CrossRef
Health-Related Quality of Life in Patients with Low-Risk Differentiated Thyroid Cancer: A Systematic Review Examining the Extent of Thyroidectomy
Kathy Bach, Palvishey Ansari, Hamayail Ansari, Nicole M. Mott, Dawn M. Elfenbein, Hunter Underwood, Susan C. Pitt
Thyroid®.2024; 34(1): 14. CrossRef
Longitudinal Changes in Quality of Life Before and After Thyroidectomy in Patients With Differentiated Thyroid Cancer
Byung Hun Kim, Soo Rack Ryu, Jin Won Lee, Chang Myeon Song, Yong Bae Ji, Seok Hyun Cho, Seung Hwan Lee, Kyung Tae
The Journal of Clinical Endocrinology & Metabolism.2024; 109(6): 1505. CrossRef
Effect of thyroid-stimulating hormone suppression on quality of life in thyroid lobectomy patients: interim analysis of a multicenter, randomized controlled trial in low- to intermediate-risk thyroid cancer patients (MASTER study)
Ja Kyung Lee, Eu Jeong Ku, Su-jin Kim, Woochul Kim, Jae Won Cho, Kyong Yeun Jung, Hyeong Won Yu, Yea Eun Kang, Mijin Kim, Hee Kyung Kim, Junsun Ryu, June Young Choi
Annals of Surgical Treatment and Research.2024; 106(1): 19. CrossRef
Five-Year Follow-Up of Health-Related Quality of Life in Differentiated Thyroid Cancer Patients Treated with Total Thyroidectomy and Radioiodine in Sweden: A Nationwide Prospective Cohort Study
Julia Winter, Erland Axelsson, Linda Björkhem-Bergman, Catharina Ihre Lundgren, Christel Hedman
Thyroid®.2024; 34(6): 713. CrossRef
Assessment of preoperative health-related quality of life in patients undergoing thyroidectomy based on patient-reported outcomes
Lei Liu, Yuqing Xiang, Lujing Xiong, Chao Li, Wei Dai, Jinchuan Hu, Chunyan Shui, Yuqiu Zhou, Xu Wang, Linjie Ma, Nan Xu, Bintao Hu, Yongcong Cai
Frontiers in Psychology.2024;[Epub] CrossRef
A Prospective Clinical Trial of Radiofrequency Ablation in Patients with Low-Risk Unifocal Papillary Thyroid Microcarcinoma Favoring Active Surveillance Over Surgery
Ji Ye Lee, Dong Gyu Na, Jung Suk Sim, Jin Yong Sung, Sun Wook Cho, Do Joon Park, Young Joo Park, Ji-hoon Kim
Thyroid®.2024; 34(9): 1126. CrossRef
Comparison of Patient-Reported Outcomes Between Active Surveillance and Immediate Lobectomy in Patients with Low-Risk Papillary Thyroid Microcarcinoma: Initial Findings from the KoMPASS Cohort
Min Joo Kim, Hojeong Won, Won Bae Kim, Eun Kyung Lee, Chang Yoon Lee, Sun Wook Cho, Han-Sang Baek, Yong Sang Lee, Yea Eun Kang, Sun Wook Kim, Ho-Cheol Kang, Jeongmin Lee, Mijin Kim, Min Ji Jeon, Jae Hoon Moon
Thyroid®.2024; 34(11): 1371. CrossRef
Optimizing surgical outcomes in papillary thyroid carcinoma with Hashimoto’s Thyroiditis: a retrospective comparative study of unilateral and total thyroidectomy
Xiaoyong Wen, Shiwei Zhou, Wu Li, Hui Li, Xiaohua Song, Yu Mao, Zeyu Li, Guangji Chen, Xiaowei Peng, Peng Wu
Scientific Reports.2024;[Epub] CrossRef
Quality of life in thyroid cancer
Torquil Watt, Thea Christoffersen, Mathilde Borring Brogaard, Jakob Bue Bjorner, Jens Bentzen, Christoffer Holst Hahn, Birte Nygaard, Ulla Feldt-Rasmussen
Best Practice & Research Clinical Endocrinology & Metabolism.2023; 37(1): 101732. CrossRef
Systematic review of health-related quality of life following thyroid cancer
Emma G Walshaw, Mike Smith, Dae Kim, Jonathan Wadsley, Anastasios Kanatas, Simon N. Rogers
Tumori Journal.2022; 108(4): 291. CrossRef
Factors affecting the health-promoting behavior of thyroid cancer survivors: comparison by stage of cancer survivorship
Kyung Ah Park, Sanghee Kim, Eui Geum Oh, Heejung Kim, Hang-Seok Chang, Soo Hyun Kim
Supportive Care in Cancer.2022; 30(4): 3429. CrossRef
Care and Management of Voice Change in Thyroid Surgery: Korean Society of Laryngology, Phoniatrics and Logopedics Clinical Practice Guideline
Chang Hwan Ryu, Seung Jin Lee, Jae-Gu Cho, Ik Joon Choi, Yoon Seok Choi, Yong Tae Hong, Soo Yeon Jung, Ji Won Kim, Doh Young Lee, Dong Kun Lee, GIljoon Lee, Sang Joon Lee, Young Chan Lee, Yong Sang Lee, Inn Chul Nam, Ki Nam Park, Young Min Park, Eui-Suk S
Clinical and Experimental Otorhinolaryngology.2022; 15(1): 24. CrossRef
Health-Related Quality of Life following Total Thyroidectomy and Lobectomy for Differentiated Thyroid Carcinoma: A Systematic Review
Vivianne Landry, Elizabeth Siciliani, Melissa Henry, Richard J. Payne
Current Oncology.2022; 29(7): 4386. CrossRef
Effect of radioiodine therapy under thyroid hormone withdrawal on health-related quality of life in patients with differentiated thyroid cancer
Hui Ming, Hui Yu, Yangbao Liu, Lihua Yang, Yuanhao Chen
Japanese Journal of Clinical Oncology.2022;[Epub] CrossRef
Thyroid disease‐specific quality of life questionnaires ‐ A systematic review
Verena Uslar, Caroline Becker, Dirk Weyhe, Navid Tabriz
Endocrinology, Diabetes & Metabolism.2022;[Epub] CrossRef
Effect of Initial Treatment Choice on 2-year Quality of Life in Patients with Low-risk Papillary Thyroid Microcarcinoma
Jae Hoon Moon, Chang Hwan Ryu, Sun Wook Cho, June Young Choi, Eun-Jae Chung, Jeong Hun Hah, Yul Hwangbo, Woo-Jin Jeong, Yuh-Seog Jung, Ji-hoon Kim, Min Joo Kim, Su-jin Kim, Yeo Koon Kim, Chang Yoon Lee, Eun Kyung Lee, Ji Ye Lee, Kyu Eun Lee, You Jin Lee,
The Journal of Clinical Endocrinology & Metabolism.2021; 106(3): 724. CrossRef
Singing voice range profile: New objective evaluation methods for voice change after thyroidectomy
Jungirl Seok, Youn Mi Ryu, Seong Ae Jo, Chang Yoon Lee, Yuh‐Seog Jung, Junsun Ryu, Chang Hwan Ryu
Clinical Otolaryngology.2021; 46(2): 332. CrossRef
A Propensity Score Matching Study Between Microwave Ablation and Radiofrequency Ablation in Terms of Safety and Efficacy for Benign Thyroid Nodules Treatment
Hao Jin, Jinrui Fan, Ligong Lu, Min Cui
Frontiers in Endocrinology.2021;[Epub] CrossRef
Adaptation transculturelle en Français du questionnaire évaluant la qualité de vie des patients opérés d’un cancer de la thyroïde : THYCA-QoL
Boris Scheller, Joseph Santini, Amélie Anota, Gilles Poissonnet, Y. Chateau, Renaud Schiappa, Danielle Benisvy, Olivier Dassonville, Alexandre Bozec, Emmanuel Chamorey
Bulletin du Cancer.2021; 108(7-8): 696. CrossRef
A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial
Eun Kyung Lee, You Jin Lee, Young Joo Park, Jae Hoon Moon, Ka Hee Yi, Koon Soon Kim, Joo Hee Lee, Sun Wook Cho, Jungnam Joo, Yul Hwangbo, Sujeong Go, Do Joon Park
Endocrinology and Metabolism.2020; 35(3): 571. CrossRef
Evaluation of Quality of Life in Patients with Differentiated Thyroid Cancer by Means of the Thyroid-Specific Patient-Reported Outcome Questionnaire: A 5-Year Longitudinal Study
Massimo Giusti, Stefano Gay, Lucia Conte, Francesca Cecoli, Lorenzo Mortara, Lara Vera, Eleonora Monti
European Thyroid Journal.2020; 9(5): 247. CrossRef
Longitudinal Assessment of Quality of Life According to Treatment Options in Low-Risk Papillary Thyroid Microcarcinoma Patients: Active Surveillance or Immediate Surgery (Interim Analysis of MAeSTro)
Sung Hye Kong, Junsun Ryu, Min Joo Kim, Sun Wook Cho, Young Shin Song, Ka Hee Yi, Do Joon Park, Yul Hwangbo, You Jin Lee, Kyu Eun Lee, Su-jin Kim, Woo-Jin Jeong, Eun-Jae Chung, Jeong Hun Hah, June Young Choi, Chang Hwan Ryu, Yuh-Seog Jung, Jae Hoon Moon,
Thyroid.2019; 29(8): 1089. CrossRef
Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro)
Jae Hoon Moon, Ji-hoon Kim, Eun Kyung Lee, Kyu Eun Lee, Sung Hye Kong, Yeo Koon Kim, Woo-jin Jung, Chang Yoon Lee, Roh-Eul Yoo, Yul Hwangbo, Young Shin Song, Min Joo Kim, Sun Wook Cho, Su-jin Kim, Eun Jae Jung, June Young Choi, Chang Hwan Ryu, You Jin Lee
Endocrinology and Metabolism.2018; 33(2): 278. CrossRef

17,383 View
332 Download
25 Web of Science
24 Crossref

Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study: Sang Myung Woo, Min Kyeong Kim, Jungnam Joo, Kyong-Ah Yoon, Boram Park, Sang-Jae Park, Sung-Sik Han, Ju Hee Lee, Eun Kyung Hong, Yun-Hee Kim, Hae Moon, Sun-Young Kong, Tae Hyun Kim, Woo Jin Lee; Cancer Res Treat. 2017;49(4):1022-1032. Published online January 19, 2017; DOI: https://doi.org/10.4143/crt.2016.495

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study assessed the feasibility and compliance of induction chemotherapy with gemcitabine and cisplatin followed by simultaneous integrated boost–intensity modulated radiotherapy (SIB-IMRT) with concurrent gemcitabine in patients with locally advanced unresectable pancreatic cancer.
Materials and Methods
In this trial, patients received induction chemotherapy consisting of gemcitabine (1,000 mg/m²) and cisplatin (25 mg/m2) on days 1, 8, and 15 of each treatment cycle. Patients were subsequently treated with gemcitabine (300 mg/m²/wk) during SIB-IMRT. The patients received total doses of 55 and 44 Gy in 22 fractions to planning target volume 1 and 2, respectively. As an ancillary study, digital polymerase chain reaction was performed to screen for the seven most common mutations in codons 12 and 13 of the KRAS oncogene of circulating cell free DNA (cfDNA).
Results
Forty-four patients were enrolled between 2012 and 2015. Of these, 33 (75%) completed the treatment. The most common toxicities during induction chemotherapy were grades 3 and 4 neutropenia (18.2%), grade 3 nausea (6.8%) and vomiting (6.8%). The most common toxicities during SIB-IMRT were grade 3 neutropenia (24.2%) and grade 3 anemia (12.1%). Ten patients (23%) underwent a curative resection after therapy. Median overall survival was significantly longer in patients who underwent curative resection (16.8 months vs. 11 months, p < 0.01). The median cfDNA concentration was significantly lower after treatment (108.5 ng/mL vs. 18.4 ng/mL, p < 0.001).
Conclusion
Induction chemotherapy with gemcitabine and cisplatin followed by concurrent SIB-IMRT was well tolerated and active.

Citations

Citations to this article as recorded by

Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma
Krishan R. Jethwa, Ed Kim, Jordan Berlin, Christopher J. Anker, Leila Tchelebi, Gerard Abood, Christopher L. Hallemeier, Salma Jabbour, Timothy Kennedy, Rachit Kumar, Percy Lee, Navesh Sharma, William Small, Vonetta Williams, Suzanne Russo
American Journal of Clinical Oncology.2024; 47(4): 185. CrossRef
Kinetics of plasma cell-free DNA as a prospective biomarker to predict the prognosis and radiotherapy effect of esophageal cancer
Y. Li, J. Wu, Y. Feng, D. Wang, H. Tao, J. Wen, F. Jiang, P. Qian, Y. Liu
Cancer/Radiothérapie.2024; 28(3): 242. CrossRef
Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic adenocarcinoma?
Olivier Caliez, Daniel Pietrasz, Feryel Ksontini, Solène Doat, Jean-Marc Simon, Jean-Christophe Vaillant, Valerie Taly, Pierre Laurent-Puig, Jean-Baptiste Bachet
Digestive and Liver Disease.2022; 54(10): 1428. CrossRef
Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review
Marisol Huerta, Susana Roselló, Luis Sabater, Ana Ferrer, Noelia Tarazona, Desamparados Roda, Valentina Gambardella, Clara Alfaro-Cervelló, Marina Garcés-Albir, Andrés Cervantes, Maider Ibarrola-Villava
Cancers.2021; 13(5): 994. CrossRef
Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR
Irina Palacín-Aliana, Noemí García-Romero, Adrià Asensi-Puig, Josefa Carrión-Navarro, Víctor González-Rumayor, Ángel Ayuso-Sacido
Biomedicines.2021; 9(8): 906. CrossRef
A review on the efficacy and safety of iodine-125 seed implantation in unresectable pancreatic cancers
Sheng-Nan Jia, Fu-Xing Wen, Ting-Ting Gong, Xin Li, Hui-Jie Wang, Ya-Min Sun, Ze-Cheng Yang
International Journal of Radiation Biology.2020; 96(3): 383. CrossRef
Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer
Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo, Eun Sang Oh, Sang Hee Youn, Hye Young Jang, Sung-Sik Han, Sang-Jae Park, Yang-Gun Suh, Sung Ho Moon, Sang Soo Kim, Dae Yong Kim
Scientific Reports.2020;[Epub] CrossRef
Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment
Kyong-Ah Yoon, Sang Myung Woo, Yun-Hee Kim, Sun-Young Kong, Min Kyoung Lee, Sung-Sik Han, Tae Hyun Kim, Woo Jin Lee, Sang-Jae Park
Gut and Liver.2019; 13(6): 683. CrossRef
Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma
Sangjoon Park, Eun Jung Lee, Chai Hong Rim, Jinsil Seong
Yonsei Medical Journal.2018; 59(4): 470. CrossRef
Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer
Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo, Hyunjung Kim, Eun Sang Oh, Ju Hee Lee, Sung-Sik Han, Sang-Jae Park, Yang-Gun Suh, Sung Ho Moon, Sang Soo Kim, Dae Yong Kim
Technology in Cancer Research & Treatment.2018;[Epub] CrossRef

10,147 View
254 Download
11 Web of Science
10 Crossref

Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer: Youngjoo Lee, Ki Hyeong Lee, Geon Kook Lee, Soo-Hyun Lee, Kun Young Lim, Jungnam Joo, Yun Jung Go, Jin Soo Lee, Ji-Youn Han; Cancer Res Treat. 2017;49(4):1001-1011. Published online January 13, 2017; DOI: https://doi.org/10.4143/crt.2016.546

Abstract PDF PubReader ePub

Purpose
This phase II study examined whether the addition of simvastatin to afatinib provides a clinical benefit compared with afatinib monotherapy in previously treated patients with nonadenocarcinomatous non-small cell lung cancer (NA-NSCLC).
Materials and Methods
Patientswith advancedNA-NSCLCwho progressed after one ortwo chemotherapy regimens were randomly assigned to a simvastatin (40 mg/day) plus afatinib (40 mg/day) (AS) arm or to an afatinib (A) arm. The primary endpoint was response rate (RR).
Results
Sixty-eight patients were enrolled (36 in the AS arm and 32 in the A arm). The RR was 5.7% (95% confidence interval [CI], 0.7 to 19.2) for AS and 9.4% (95% CI, 2.0 to 25.0) for A (p=0.440). In arms AS and A, the median progression-free survival (PFS) was 1.0 versus 3.6 months (p=0.240) and the overall survival was 10.0 months versus 7.0 months (p=0.930), respectively. Skin rash, stomatitis, and diarrhea were the most common adverse events in both arms. More grade 3 or 4 diarrhea was observed in arm A (18.8% vs. 5.6% in arm AS). In all patients, the median PFS for treatment including afatinib was not correlated with the status of epidermal growth factor receptor (EGFR) mutation (p=0.122), EGFR fluorescence in situ hybridization (p=0.944), or EGFR immunohistochemistry (p=0.976). However, skin rash severity was significantly related to the risk of progression for afatinib (hazard ratio for skin rash grade ≥ 2 vs. grade < 2, 0.44; 95% CI, 0.25 to 0.78; p=0.005).
Conclusion
There were no significant differences in the efficacy between AS and A arms in patients with NA-NSCLC.

Citations

Citations to this article as recorded by

Statins in the Cause and Prevention of Cancer: Confounding by Indication and Mediation by Rhabdomyolysis and Phosphate Toxicity
Ronald B. Brown
Journal of Cardiovascular Development and Disease.2024; 11(9): 296. CrossRef
Unraveling lipid metabolism reprogramming for overcoming drug resistance in melanoma
Ruilong Wang, Qin Yan, Xiao Liu, Jinfeng Wu
Biochemical Pharmacology.2024; 223: 116122. CrossRef
Cardiovascular/anti‐inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta‐analysis of randomized trials
David J. Benjamin, Alyson Haslam, Vinay Prasad
Cancer Medicine.2024;[Epub] CrossRef
The preventative effects of statin on lung cancer development in patients with idiopathic pulmonary fibrosis using the National Health Insurance Service Database in Korea
Yoo Jung Lee, Nayoon Kang, Junghyun Nam, Eung Gu Lee, Jiwon Ryoo, Soon Seog Kwon, Yong Hyun Kim, Hye Seon Kang, Tsai-Ching Hsu
PLOS ONE.2024; 19(3): e0299484. CrossRef
DHCR24 in Tumor Diagnosis and Treatment: A Comprehensive Review
Xin Fu, Zhaosong Wang
Technology in Cancer Research & Treatment.2024;[Epub] CrossRef
β-blockers and statins: exploring the potential off-label applications in breast, colorectal, prostate, and lung cancers
Pedro Gabriel Senger Braga, Janaína da Silva Vieira, Aline Rachel Bezerra Gurgel, Patricia Chakur Brum
Frontiers in Pharmacology.2024;[Epub] CrossRef
The effects of statins in patients with advanced-stage cancers - a systematic review and meta-analysis
Qiang Zhou, Zhihua Jiao, Yuxi Liu, Peter N. Devreotes, Zhenyu Zhang
Frontiers in Oncology.2023;[Epub] CrossRef
Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients
Claes R. Andersson, Jiawei Ye, Kristin Blom, Mårten Fryknäs, Rolf Larsson, Peter Nygren
Anti-Cancer Drugs.2023; 34(1): 92. CrossRef
New insights into the therapeutic potentials of statins in cancer
Chengyu Liu, Hong Chen, Bicheng Hu, Jiajian Shi, Yuchen Chen, Kun Huang
Frontiers in Pharmacology.2023;[Epub] CrossRef
Functional significance of cholesterol metabolism in cancer: from threat to treatment
Mingming Xiao, Jin Xu, Wei Wang, Bo Zhang, Jiang Liu, Jialin Li, Hang Xu, Yingjun Zhao, Xianjun Yu, Si Shi
Experimental & Molecular Medicine.2023; 55(9): 1982. CrossRef
Simvastatin Enhanced Anti-tumor Effects of Bevacizumab against Lung Adenocarcinoma A549 Cells via Abating HIF-1α-Wnt/β-Catenin Signaling Pathway
Xin Tu, Jian Zhang, Wei Yuan, Xia Wu, Zhi Xu, Cuo Qing
Anti-Cancer Agents in Medicinal Chemistry.2023; 23(19): 2083. CrossRef
Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs
Kush K. Patel, Khosrow Kashfi
Biochemical Pharmacology.2022; 196: 114654. CrossRef
Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer
Yoichi Morofuji, Shinsuke Nakagawa, Kenta Ujifuku, Takashi Fujimoto, Kaishi Otsuka, Masami Niwa, Keisuke Tsutsumi
Pharmaceuticals.2022; 15(2): 151. CrossRef
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
Kamal Eltayeb, Silvia La Monica, Marcello Tiseo, Roberta Alfieri, Claudia Fumarola
Cells.2022; 11(3): 413. CrossRef
Effect of Statins on Lung Cancer Molecular Pathways: A Possible Therapeutic Role
Gianmarco Marcianò, Caterina Palleria, Alessandro Casarella, Vincenzo Rania, Emanuele Basile, Luca Catarisano, Cristina Vocca, Luigi Bianco, Corrado Pelaia, Erika Cione, Bruno D’Agostino, Rita Citraro, Giovambattista De Sarro, Luca Gallelli
Pharmaceuticals.2022; 15(5): 589. CrossRef
The effects of epithelial–mesenchymal transitions in COPD induced by cigarette smoke: an update
Xiaoshan Su, Weijing Wu, Zhixing Zhu, Xiaoping Lin, Yiming Zeng
Respiratory Research.2022;[Epub] CrossRef
Scientific Research Directions on the Histopathology and Immunohistochemistry of the Cutaneous Squamous Cell Carcinoma: A Scientometric Study
Iuliu Gabriel Cocuz, Maria Elena Cocuz, Angela Repanovici, Adrian-Horațiu Sabău, Raluca Niculescu, Andreea-Cătălina Tinca, Vlad Vunvulea, Corina Eugenia Budin, Andreea Raluca Szoke, Maria Cătălina Popelea, Raluca Moraru, Titiana Cornelia Cotoi, Ovidiu Sim
Medicina.2022; 58(10): 1449. CrossRef
Lipid metabolism and cancer
Xueli Bian, Rui Liu, Ying Meng, Dongming Xing, Daqian Xu, Zhimin Lu
Journal of Experimental Medicine.2021;[Epub] CrossRef
Simvastatin-romidepsin combination kills bladder cancer cells synergistically
Kazuki Okubo, Kosuke Miyai, Kimi Kato, Takako Asano, Akinori Sato
Translational Oncology.2021; 14(9): 101154. CrossRef
Statins Decrease Programmed Death-Ligand 1 (PD-L1) by Inhibiting AKT and β-Catenin Signaling
Woo-Jin Lim, Mingyu Lee, Yerin Oh, Xue-Quan Fang, Sujin Lee, Chang-Hoon Lim, Jooho Park, Ji-Hong Lim
Cells.2021; 10(9): 2488. CrossRef
ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells
Jillian Hattaway Luttman, Jacob P. Hoj, Kevin H. Lin, Jiaxing Lin, Jing Jin Gu, Clay Rouse, Amanda G. Nichols, Nancie J. MacIver, Kris C. Wood, Ann Marie Pendergast
Cell Reports.2021; 37(4): 109880. CrossRef
Adjuvant statin therapy for oesophageal adenocarcinoma: the STAT-ROC feasibility study
L. Alexandre, A. B. Clark, S. Walton, M. P. Lewis, B. Kumar, E. C. Cheong, H. Warren, S. S. Kadirkamanathan, S. L. Parsons, S. M. Dresner, E. Sims, M. Jones, M. Hammond, M. Flather, Y. K. Loke, A. M. Swart, A. R. Hart
BJS Open.2020; 4(1): 59. CrossRef
Whether statin use improves the survival of patients with glioblastoma?
Yonglin Xie, Qin Lu, Cameron Lenahan, Shuxu Yang, Daoyang Zhou, Xuchen Qi
Medicine.2020; 99(9): e18997. CrossRef
Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
Kazuki Okubo, Makoto Isono, Kosuke Miyai, Takako Asano, Akinori Sato
Cancer Science.2020; 111(1): 112. CrossRef
Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?
Paolo Gelosa, Laura Castiglioni, Marina Camera, Luigi Sironi
Biochemical Pharmacology.2020; 177: 113895. CrossRef
Attenuation of the pro-inflammatory signature of lung cancer-derived mesenchymal stromal cells by statins
Sabine Galland, Patricia Martin, Giulia Fregni, Igor Letovanec, Ivan Stamenkovic
Cancer Letters.2020; 484: 50. CrossRef
Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials
John P. Thomas, Yoon K. Loke, Leo Alexandre
European Journal of Clinical Pharmacology.2020; 76(12): 1639. CrossRef
Statins as Anticancer Agents in the Era of Precision Medicine
Joseph Longo, Jenna E. van Leeuwen, Mohamad Elbaz, Emily Branchard, Linda Z. Penn
Clinical Cancer Research.2020; 26(22): 5791. CrossRef
Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway
Sheng Zhou, Huanji Xu, Qiulin Tang, Hongwei Xia, Feng Bi
Molecular Cancer Therapeutics.2020; 19(1): 135. CrossRef
Repurposed Drugs Trials by Cancer Type
Joseph C. Murray, Benjamin Levy
The Cancer Journal.2019; 25(2): 127. CrossRef
Diverse Stakeholders of Tumor Metabolism: An Appraisal of the Emerging Approach of Multifaceted Metabolic Targeting by 3-Bromopyruvate
Saveg Yadav, Shrish Kumar Pandey, Yugal Goel, Mithlesh Kumar Temre, Sukh Mahendra Singh
Frontiers in Pharmacology.2019;[Epub] CrossRef
Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis
Cheng-Wei Chou, Ching-Heng Lin, Tzu-Hung Hsiao, Chia-Chien Lo, Chih-Ying Hsieh, Cheng-Chung Huang, Yuh-Pyng Sher
Scientific Reports.2019;[Epub] CrossRef
Drug Repurposing of Metabolic Agents in Malignant Glioma
Corinna Seliger, Peter Hau
International Journal of Molecular Sciences.2018; 19(9): 2768. CrossRef
The Effect of Statin Added to Systemic Anticancer Therapy: A Meta-Analysis of Randomized, Controlled Trials
Hyun Joo Jang, Hyeong Su Kim, Jung Han Kim, Jin Lee
Journal of Clinical Medicine.2018; 7(10): 325. CrossRef
Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials
Mohammed A. M. Farooqi, Nikita Malhotra, Som D. Mukherjee, Stephanie Sanger, Sukhbinder K. Dhesy-Thind, Peter Ellis, Darryl P. Leong, Robert M. Lafrenie
PLOS ONE.2018; 13(12): e0209486. CrossRef
Synergistic effect of receptor-interacting protein 140 and simvastatin on the inhibition of proliferation and survival of hepatocellular carcinoma cells
Kun Xia, Panpan Zhang, Jian Hu, Huan Hou, Mingdi Xiong, Junping Xiong, Nianlong Yan
Oncology Letters.2018;[Epub] CrossRef

12,350 View
347 Download
43 Web of Science
36 Crossref

Postmastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-Based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418): Yeon-Joo Kim, Won Park, Boram Ha, Boram Park, Jungnam Joo, Tae Hyun Kim, In Hae Park, Keun Seok Lee, Eun Sook Lee, Kyung Hwan Shin, Haeyoung Kim, Jeong Il Yu, Doo Ho Choi, Seung Jae Huh, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha; Cancer Res Treat. 2017;49(4):927-936. Published online December 26, 2016; DOI: https://doi.org/10.4143/crt.2016.508

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy.
Materials and Methods
We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010.
Results
We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [–]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081).
Conclusion
PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane-based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3.

Citations

Citations to this article as recorded by

Does Post-Mastectomy Radiotherapy Confer Survival Benefits on Patients With 1-3 Clinically Positive Lymph Nodes Rendered Pathologically Negative After Neoadjuvant Systemic Chemotherapy: Consensus from A Pooled Analysis?
Munaser Alamoodi
European Journal of Breast Health.2024; 20(2): 81. CrossRef
Effect of postmastectomy radiotherapy on T1-2N1M0 triple-negative breast cancer
Lin-Yu Xia, Wei-Yun Xu, Yan Zhao, Sudeep Gupta
PLOS ONE.2022; 17(6): e0270528. CrossRef
Suggestion for the omission of post-mastectomy chest wall radiation therapy in patients who underwent skin-sparing/nipple-sparing mastectomy
Nalee Kim, Won Park, Won Kyung Cho, Hae Young Kim, Doo Ho Choi, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Goo-Hyun Mun, Jai-Kyong Pyon, Byung-Joon Jeon
The Breast.2022; 66: 54. CrossRef
Post-mastectomy radiation therapy in breast cancer patients with 1–3 positive lymph nodes: No one size fits all
Majd Kayali, Joseph Abi Jaoude, Arafat Tfayli, Nagi El Saghir, Philip Poortmans, Youssef H. Zeidan
Critical Reviews in Oncology/Hematology.2020; 147: 102880. CrossRef
The survival benefit of postmastectomy radiotherapy for breast cancer patients with T1-2N1 disease according to molecular subtype
Jinli Wei, Yizhou Jiang, Zhimin Shao
The Breast.2020; 51: 40. CrossRef
The effect of postmastectomy radiotherapy in node-positive triple-negative breast cancer
Lei Zhang, Ru Tang, Jia-Peng Deng, Wen-Wen Zhang, Huan-Xin Lin, San-Gang Wu, Zhen-Yu He
BMC Cancer.2020;[Epub] CrossRef
Comparison of Breast Conserving Surgery Followed by Radiation Therapy with Mastectomy Alone for Pathologic N1 Breast Cancer Patients in the Era of Anthracycline Plus Taxane-Based Chemotherapy: A Multicenter Retrospective Study (KROG 1418)
Gyu Sang Yoo, Won Park, Jeong Il Yu, Doo Ho Choi, Yeon-Joo Kim, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha
Cancer Research and Treatment.2019; 51(3): 1041. CrossRef
Effect of postmastectomy radiotherapy on triple-negative breast cancer with T1-2 and 1-3 positive axillary lymph nodes: a population-based study using the SEER 18 database
Jie Zhang, Xiao-Xiao Wang, Jun-Yu Lian, Chuan-Gui Song
Oncotarget.2019; 10(50): 5245. CrossRef
Local and regional recurrence following mastectomy in breast cancer patients with 1–3 positive nodes: implications for postmastectomy radiotherapy volume
Shin-Hyung Park, Jeeyeon Lee, Jeong Eun Lee, Min Kyu Kang, Mi Young Kim, Ho Yong Park, Jin Hyang Jung, Yee Soo Chae, Soo Jung Lee, Jae-Chul Kim
Radiation Oncology Journal.2018; 36(4): 285. CrossRef

11,314 View
346 Download
9 Web of Science
9 Crossref

Comparison of Quality of Life and Sexuality between Cervical Cancer Survivors and Healthy Women: Yumi Lee, Myong Cheol Lim, Se Ik Kim, Jungnam Joo, Dong Ock Lee, Sang-Yoon Park; Cancer Res Treat. 2016;48(4):1321-1329. Published online February 12, 2016; DOI: https://doi.org/10.4143/crt.2015.425

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to compare quality of life (QoL) and sexual functioning between sexually active cervical cancer survivors and healthy women.
Materials and Methods
In this cross-sectional study, propensity-score-matched cervical cancer survivors (n=104) and healthy women (n=104) were compared. All women had engaged in sexual activity within the previous 3 months, and cervical cancer survivors showed no evidence of disease after primary treatment. QoL and sexual functioning were assessed using three questionnaires; the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), Cervical Cancer Module (EORTC QLQ-CX24), and the Female Sexual Function Index (FSFI).
Results
Significantly higher scores for lymphedema were observed in the cervical cancer survivors group compared with the healthy women group (mean, 20.2 vs. 12.2; p < 0.05). Sexuality, both in terms of sexual activity, sexual enjoyment, and sexual worry (EORTC QLQ-CX24), and in terms of desire, arousal, lubrication, orgasm, satisfaction, and pain (FSFI) were similar between the groups. When the scale of sexual/vaginal functioning in EORTC QLQ-CX24 was divided into individual questions, cervical cancer survivors reported shorter vaginal length than the control group, but without statistical significance (mean, 80.6 vs. 85.4; p=0.077).
Conclusion
Compared with healthy women, sexuality was not impaired in cervical cancer survivors who showed no evidence of disease after primary treatment and engaging in sexual activity. Further prospective cohort studies are warranted to confirm this finding.

Citations

Citations to this article as recorded by

Sexual quality of life between healthy women and women with gynecological cancer: Results of a hospital‐based case–control study in Türkiye
Ekin Dila Topaloğlu Ören, Selin Kiziltaş
Journal of Obstetrics and Gynaecology Research.2024; 50(3): 456. CrossRef
Quality of life in long-term cervical cancer survivors compared with healthy women and women with benign gynecological disorders
Jorge Cea García, Inmaculada Rodríguez Jiménez, Francisco Márquez Maraver, Laura Ríos-Pena, M. Carmen Rubio Rodríguez
European Journal of Obstetrics & Gynecology and Reproductive Biology.2024; 297: 78. CrossRef
Pre- and Post-Treatment Quality of Life Among Patients with Advanced Stage Cervical Cancer at Tikur Anbessa Specialized Hospital, Ethiopia
Roza Teshome, Irene Yang, Edom Woldetsadik, Eshetu Girma, Melinda Higgins, Jessica Wells
Cancer Management and Research.2024; Volume 16: 311. CrossRef
Female sexual function in long-term cervical cancer survivors compared with healthy women and women affected by benign gynecological disorders
Jorge Cea García, Francisco Márquez Maraver, Inmaculada Rodríguez Jiménez, Laura Ríos-Pena, M. Carmen Rubio Rodríguez
European Journal of Obstetrics & Gynecology and Reproductive Biology.2024; 299: 43. CrossRef
Prevalence of sexual dysfunction in women with cervical cancer: a systematic review and meta-analysis
Maolin Qian, Lan Wang, Jiajun Xing, Xiao Shan, Juan Wu, Xiaoqin Liu
Psychology, Health & Medicine.2023; 28(2): 494. CrossRef
Trends and future projections of cervical cancer‐related outcomes in Japan: What happens if the HPV vaccine program is not implemented?
Atsuko Sakakibara, Takeo Nakayama, Hiroyuki Uchida, Youichi Odagiri, Yuri Ito, Toshiro Katayama, Yutaka Ueda, Toshihiro Higuchi, Koichi Terakawa, Kunihiko Matsui, Kikuko Miyazaki, Ikuo Konishi
International Journal of Cancer.2023; 152(9): 1863. CrossRef
Post Treatment Sexual Function and Quality of Life of Patients Affected by Cervical Cancer: A Systematic Review
Stefano Cianci, Mattia Tarascio, Martina Arcieri, Marco La Verde, Canio Martinelli, Vito Andrea Capozzi, Vittorio Palmara, Ferdinando Gulino, Salvatore Gueli Alletti, Giuseppe Caruso, Stefano Restaino, Giuseppe Vizzielli, Carmine Conte, Marco Palumbo, Alf
Medicina.2023; 59(4): 704. CrossRef
Association between cervical cancer-related anxiety and depression symptoms and health-related quality of life: A Moroccan cross-sectional study
Asmaa Azizi, Doha Achak, Amal Boutib, Samia Chergaoui, Elmadani Saad, Abderraouf Hilali, Amr S. Soliman, Ibtissam Youlyouz-Marfak, Abdelghafour Marfak
Clinical Epidemiology and Global Health.2023; 22: 101328. CrossRef
Impacto del cáncer de cuello uterino en la sexualidad femenina
Camilla R. Albæk-Jakobsen, Pere Fusté-Brull
Medicina.2023; 24(2): 21. CrossRef
Sexual Behaviors and Intimate Relationships of Sexual Partners of Young Patients with Early-Stage Cervical Cancer: A Qualitative Study
Mingyue Li, Dongyang Wang, Jiaxiang Huang, Shunlian Luan, Qinghua Wang
International Journal of General Medicine.2023; Volume 16: 5377. CrossRef
Long-term Quality of Life and Sexual Function After Neoadjuvant Chemotherapy and Radical Surgery for Locally Advanced Cervical Cancer
Innocenza Palaia, Giusi Santangelo, Giuseppe Caruso, Giorgia Perniola, Valentina Tibaldi, Ludovico Muzii, Pierluigi Benedetti Panici, Violante Di Donato
The Journal of Sexual Medicine.2022; 19(4): 613. CrossRef
The Importance of Social Support, Optimism and Resilience on the Quality of Life of Cancer Patients
Iván Ruiz-Rodríguez, Isabel Hombrados-Mendieta, Anabel Melguizo-Garín, María José Martos-Méndez
Frontiers in Psychology.2022;[Epub] CrossRef
Relationship of sexual quality of life and mental well-being in undergraduate women in a Canadian university
Niki Oveisi, Zeba Khan, Lori A. Brotto
The Canadian Journal of Human Sexuality.2022; 31(3): 422. CrossRef
Longitudinal Health-Related Quality of Life Study among Cervical Cancer Patients Treated with Radiotherapy
Małgorzata Pasek, Lilia Suchocka, Grażyna Osuch-Pęcak, Konrad Muzykiewicz, Ewa Iwańska, Helena Kaducakowa, Anna Goździalska, Magdalena Goździalska
Journal of Clinical Medicine.2021; 10(2): 226. CrossRef
Sexual Function and the Role of Sexual Communication in Women Diagnosed with Cervical Cancer: A Systematic Review
Magdalena Liberacka-Dwojak, Paweł Izdebski
International Journal of Sexual Health.2021; 33(3): 385. CrossRef
Contribution of Sociodemographic, Clinical, and Psychological Variables to Quality of Life in Women with Cervical Cancer in the Follow-Up Phase
Ana Clara Lopes, Rosário Bacalhau, Martim Santos, Marta Pereira, M. Graça Pereira
Journal of Clinical Psychology in Medical Settings.2020; 27(3): 603. CrossRef
Health-related quality of life and associated factors among cervical cancer patients at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia
Liya Teklu Araya, Teferi Gedif Fenta, Beate Sander, Girma Tekle Gebremariam, Gebremedhin Beedemariam Gebretekle
Health and Quality of Life Outcomes.2020;[Epub] CrossRef
Le retentissement du cancer utérin et ses traitements sur la sexualité
A. Ghorbel, A. Yousfi, R. Abidi, S. Yahyaoui, S. Zaraa, K. Mahjoubi, A. Belaid, W. Gargouri, C. Nasr
Sexologies.2020; 29(4): 186. CrossRef
Survey of the desire to have children and engage in sexual activity after trachelectomy among young Japanese women with early‐stage cervical cancer
Hideaki Yahata, Kenzo Sonoda, Kaoru Okugawa, Hiroshi Yagi, Tatsuhiro Ohgami, Masafumi Yasunaga, Ichiro Onoyama, Eisuke Kaneki, Kazuo Asanoma, Kiyoko Kato
Journal of Obstetrics and Gynaecology Research.2019; 45(11): 2255. CrossRef
Qualidade de vida e fatores associados em mulheres sobreviventes ao câncer do colo do útero
Camila Soares Lima Corrêa, Isabel Cristina Gonçalves Leite, Anna Paula Silva Andrade, Simone Meira Carvalho, Ricardo Miranda Borges, Maximiliano Ribeiro Guerra
HU Revista.2019; 43(4): 307. CrossRef
The EOLO (End-of-Life Ovarian Cancer) Study: Approach to Ovarian Cancer Patients at the End of Life
Innocenza Palaia, Federica Tomao, Giusi Santangelo, Anna Di Pinto, Carolina Maria Sassu, Giorgia Perniola, Angela Musella, Violante Di Donato, Antonella Giancotti, Pierluigi Benedetti Panici
Oncology.2019; 97(5): 306. CrossRef
Vaginal development and sexual functioning in young women after stem cell transplantation, chemotherapy, and/or radiotherapy for childhood hematological diseases
Fausta Beneventi, Elena Locatelli, Margherita Simonetta, Chiara Cavagnoli, Raffaella Pampuri, Camilla Bellingeri, Irene De Maggio, Beatrice Ruspini, Santina Recupero, Giovanna Giorgiani, Arsenio Spinillo
Bone Marrow Transplantation.2018; 53(9): 1157. CrossRef
Cross-cultural adaptation and validation of the Functional Assessment of Chronic Illness Therapy – Cervical Dysplasia (FACIT-CD) questionnaire for Serbian women
Vesna Kesić, Radmila Sparić, Rafal Watrowski, Jelena Dotlić, Radomir Stefanović, Gorica Marić, Tatjana Pekmezović
European Journal of Obstetrics & Gynecology and Reproductive Biology.2018; 226: 7. CrossRef
Percutaneous parametrial dose escalation in women with advanced cervical cancer: feasibility and efficacy in relation to long-term quality of life
Sati Akbaba, Jan Tobias Oelmann-Avendano, Tilman Bostel, Harald Rief, Nils Henrik Nicolay, Juergen Debus, Katja Lindel, Robert Foerster
Radiology and Oncology.2018; 52(3): 320. CrossRef
Attitudes Regarding HPV Vaccinations of Children among Mothers with Adolescent Daughters in Korea
Kyong-No Lee, Kylie Hae-Jin Chang, Seong-Sik Cho, Sung-Ho Park, Sung Taek Park
Journal of Korean Medical Science.2017; 32(1): 130. CrossRef
Impact of Ospemifene on Quality of Life and Sexual Function in Young Survivors of Cervical Cancer: A Prospective Study
Nicoletta De Rosa, Giada Lavitola, Pierluigi Giampaolino, Ilaria Morra, Carmine Nappi, Giuseppe Bifulco
BioMed Research International.2017; 2017: 1. CrossRef
Körperliche Beschwerden und psychosoziale Folgen nach einer Zervixkarzinomerkrankung
Kristina Geue, Elisabeth Sowa, Susanne Kuhnt
Der Onkologe.2016; 22(10): 780. CrossRef

13,408 View
390 Download
31 Web of Science
27 Crossref

Nucleotide Excision Repair Gene ERCC2 and ERCC5 Variants Increase Risk of Uterine Cervical Cancer: Jungnam Joo, Kyong-Ah Yoon, Tomonori Hayashi, Sun-Young Kong, Hye-Jin Shin, Boram Park, Young Min Kim, Sang-Hyun Hwang, Jeongseon Kim, Aesun Shin, Joo-Young Kim; Cancer Res Treat. 2016;48(2):708-714. Published online June 22, 2015; DOI: https://doi.org/10.4143/crt.2015.098

Abstract PDF Supplementary Material PubReader ePub

Purpose
Defects in the DNA damage repair process can cause genomic instability and play an important role in cervical carcinogenesis. The purpose of this study was to analyze the association of 29 candidate single nucleotide polymorphisms (SNPs) in genes in the DNA repair pathway, TP53, and TP53BP1 with the risk of cervical cancer.
Materials and Methods
Twenty-nine SNPs in four genes in the DNA repair pathway (ERCC2, ERCC5, NBS1, and XRCC1), TP53, and TP53BP1 were genotyped for 478 cervical cancer patients and 922 healthy control subjects, and their effects on cervical carcinogenesis were analyzed.
Results
The most significant association was found for rs17655 in ERCC5, with an age-adjusted p-value < 0.0001, for which a strong additive effect of the risk allele C was observed (odds ratio, 2.01 for CC to GG). On the other hand, another significant polymorphism rs454421 in ERCC2 showed a dominant effect (odds ratio, 1.68 for GA+AA to GG) with an age-adjusted p-value of 0.0009. The association of these polymorphisms remained significant regardless of the age of onset. The significant result for rs17655 was also consistent for subgroups of patients defined by histology and human papillomavirus (HPV) types. However, for rs454421, the association was observed only in patients with squamous cell carcinoma and non-HPV 18 type.
Conclusion
The results of this study show a novel association of cervical cancer and the genes involved in the nucleotide excision pathway in the Korean population.

Citations

Citations to this article as recorded by

KIAA1549 promotes the development and chemoresistance of colorectal cancer by upregulating ERCC2
Feng Ye, Yuwen Xie, Mingdao Lin, Yang Liu, Yuan Fang, Keli Chen, Yaowei Zhang, Yi Ding
Molecular and Cellular Biochemistry.2024; 479(3): 629. CrossRef
Elucidation of Increased Cervical Cancer Risk Due to Polymorphisms in XRCC1 (R399Q and R194W), ERCC5 (D1104H), and NQO1 (P187S)
Agneesh Pratim Das, Sandeep Saini, Shrishty Tyagi, Nisha Chaudhary, Subhash Mohan Agarwal
Reproductive Sciences.2023; 30(4): 1118. CrossRef
Genetic polymorphisms in DNA repair genes and their association with risk of cervical cancer: A systematic review and meta‐analysis
Xueting Shao, Xiaole Yang, Ying Liu, Qingxia Song, Xin Pan, Wansu Chen, Wei Jiang, Dan Xu, Yuanyuan Song, Renshou Chen
Journal of Obstetrics and Gynaecology Research.2022; 48(9): 2405. CrossRef
Association of nonsynonymous SNPs of nucleotide excision repair genes ERCC4 rs1800067 (G/A) and ERCC5 rs17655 (G/C) as predisposing risk factors for gallbladder cancer
Kumari Anjali, Tarun Kumar, Puneet Kumar, Gopeshwar Narayan, Sunita Singh
Digestive and Liver Disease.2022; 54(11): 1533. CrossRef
Rare germline variants in DNA repair-related genes are accountable for papillary thyroid cancer susceptibility
Catia Mio, Antonella Verrienti, Valeria Pecce, Marialuisa Sponziello, Giuseppe Damante
Endocrine.2021; 73(3): 648. CrossRef
A meta-analysis of XRCC1 single nucleotide polymorphism and susceptibility to gynecological malignancies
Xue Qin Zhang, Li Li
Medicine.2021; 100(50): e28030. CrossRef
The association of integration patterns of human papilloma virus and single nucleotide polymorphisms on immune- or DNA repair-related genes in cervical cancer patients
Jungnam Joo, Yosuke Omae, Yuki Hitomi, Boram Park, Hye-Jin Shin, Kyong-Ah Yoon, Hiromi Sawai, Makoto Tsuiji, Tomonori Hayashi, Sun-Young Kong, Katsushi Tokunaga, Joo-Young Kim
Scientific Reports.2019;[Epub] CrossRef
The Pivotal Role of DNA Repair in Infection Mediated-Inflammation and Cancer
Ayse Z. Sahan, Tapas K. Hazra, Soumita Das
Frontiers in Microbiology.2018;[Epub] CrossRef
Somatic mutation load and spectra: A record of DNA damage and repair in healthy human cells
Natalie Saini, Dmitry A. Gordenin
Environmental and Molecular Mutagenesis.2018; 59(8): 672. CrossRef

12,256 View
91 Download
13 Web of Science
9 Crossref

First
Prev
Page of 1
Next
Last

Search